Regulatory and Operational Considerations for Pediatric Formulation Development
Tuesday, June 23, 2020 | Noon CST
This webinar will include a 45 minute presentation and 10 to 15 minutes of Q&A.
Healthcare providers and regulators have placed increasing importance on the inclusion of more pediatric focused formulations for new and current products on the markets and this has ushered in strong regulatory requirements regarding pediatric product safety, product usability and the reduction of dosing risk. As the regulatory requirements become more complex the industry has seen a rise in applicable tools to assist manufacturers in the re-formulation and development of child safe product variations; however, CMC teams must remain current on the data and justifications that must be submitted for regulatory approval of new treatments.
- Regulatory expectations for pediatric formulations
- The Best Pharmaceutical for Children’s Act
- Pediatric Research Equity Act
- Considerations during pediatric formulation
- Delivery method
- Explore applicability for a pediatric waiver
This webinar is available to single attendees for $249.
For teams, three logins are available for $395.
Regulatory Affairs CMC
Global Regulatory Affairs CMC
Senior Manager, CMC Regulatory Affairs
Dan is currently Senior Manager, CMC Regulatory Affairs at Taiho Oncology, Inc. Prior to joining Taiho, Dan served as Director of Chemistry at Novatia, LLC. He also worked in chemical process R&D at Teva Pharmaceuticals (formerly Cephalon, Inc.), Pharmacopeia, Inc., and Merck & Co., Inc. Dan received his Ph.D. in Chemistry from the University of Pennsylvania and an A.B. in Chemistry from Princeton University. Dan lives in Doylestown, PA with his wife and three children.
For More Information, Contact:
Division Director, Life Science Programs
+1 (312) 224-1693